Fitusiran for hemophilia b

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 2 registered trials.

Why this status

  1. 31 Jan 2018: Trial registered, NCT03417102
  2. 14 Feb 2018: Trial started, NCT03417102

The trials

NCT02554773: An Open-label Extension Study of an Investigational Drug, Fitusiran, in Patients With Moderate or Severe Hemophilia A or B

State
Completed
Phase
Phase 1 and Phase 2
People
34 taking part
Started
18 Sep 2015
Primary completion
21 Mar 2023
Arms
Fitusiran
Results
Posted on the registry
  1. 18 Sep 2015: Trial registered
  2. 18 Sep 2015: Trial started
  3. 21 Mar 2023: Trial completed
  4. 5 Jun 2024: Trial results posted

NCT03417102: A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With Inhibitors

State
Completed
Phase
Phase 3
People
60 taking part
Started
14 Feb 2018
Primary completion
25 Nov 2020
Arms
Fitusiran 80 mg Prophylaxis
Results
Posted on the registry
  1. 31 Jan 2018: Trial registered
  2. 14 Feb 2018: Trial started
  3. 23 Jun 2021: Trial completed
  4. 21 Dec 2021: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as Fitusiran (SAR439774).

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.